New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
Primary care clinicians routinely counsel patients whose eating patterns reflect diverse cultural traditions. This resource offers practical, evidence-based strategies for supporting balanced nutrition...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
